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Aims: This study aimed to explore breast cancer patients' understanding and acceptability of
implanted biosensors (BS) within the primary tumour to personalise adjuvant radiotherapy, and
to determine optimal design and number of BS, and evaluate potential clinical benefits as well
as concerns about tolerance, toxicity, dwell time, and confidentiality of data.
Patients and methods: A total of 32 patients treated by surgery (29 breast conserving, 3
mastectomy), postoperative radiotherapy and systemic therapy for early breast cancer, were
recruited from a posttreatment radiotherapy clinic at a cancer centre. Patients participated in
semistructured interviews. Interview transcripts were analysed using qualitative methods.
Results: Participants were aged 39 to 87 years, with a median age of 62 years. Most
(N = 23[72%]) were unfamiliar with biosensors. The majority (N = 29[90.6%]) were supportive
of the technology's potential use in future breast cancer treatment and were willing to accept bio-
sensors (N = 28[88%]) if they were endorsed by their breast cancer consultant. Only 3 patients
expressed concerns, predominantly about uncertainties on their role in the diagnostic and treat-
ment pathway. Patients were flexible about the size and shape of BS, but had a preference for
small size (N = 28 [87.5%]). Most (N = 22[69%]) would accept implantation of more than 5 BS
and were flexible (N = 22[69%]) about indefinite dwell time. Patients had a strong preference
for wireless powering of the BS (N = 28[87.5%]). Few had concerns about loss of confidentiality
of data collected. All patients considered biosensors to be potentially of important clinical benefit.
Conclusions: While knowledge of biosensors was limited, patients were generally supportive
of biosensors implanted within the primary tumour to collect data that might personalise and
improve breast cancer radiotherapy in future.
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acceptability1 | INTRODUCTION
Radiotherapy uses ionising radiation, normally delivered by treatment
machines (linear accelerators, LINACs), to kill or control cancer cells
by damaging their DNA. If radiotherapy is given to the organ contain-
ing cancer after surgery, to kill any residual cancer cells, it is called- - - - - - - - - - - - - - - - - - - - - - - - - - -
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ished by Wiley Periodicals, Inc.“adjuvant.” Radiation beams can be shaped to treat the organ (for
example, the breast) once the cancer has been removed by surgery
while minimising dosage to other organs such as the heart. Prior to a
course of radiotherapy, a dose “map” is created to show the distribu-
tion of the X‐ray dose within the breast. Typically for breast cancer,
after surgery, small daily doses of radiation based on this dose “map”- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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FIGURE 1 Biosensors in radiation treatment of cancer. A, Group of
cancer cells. B, Radio‐resistant hypoxic (1) and radiosensitive (2) cells
with immune (3) and vascular (4) cells in the tumour microenvironment.
C, Stereotactic insertion of biosensors into the microenvironment. D,
Signal output (5) from biosensors in hypoxic radio‐resistant zones. E,
Differential deposition of radiation treatment to hypoxic radio‐
resistant zones
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over 3 to 4 weeks.1 However, each dose is not adjusted to the chang-
ing biology of the cancer during treatment. There is now increased
scientific interest in adapting radiotherapy to the biology of the
individual patient and his/her tumour to improve clinical outcomes.
Adjuvant radiotherapy remains, along with surgery and systemic
therapy, a cornerstone of the treatment of early breast cancer. Adju-
vant radiotherapy roughly halves the risk of first recurrence after
breast conserving surgery2 and improves survival rates both after
breast conserving surgery2 and mastectomy.3 Selection for adjuvant
radiotherapy after mastectomy is based on clinico‐pathological factors
(eg, tumour size, and spread to local lymph nodes). However, there are
no reliable measures (biomarkers) of a tumour's likely response to
radiotherapy to predict which patients with cancer in general, or breast
cancer in particular, are likely to respond to radiotherapy.4 There is
increasing interest in treating breast tumours before surgery, where
the intact tumour can be used to monitor response. This approach is
well established for hormonal and chemotherapy to shrink breast
cancers before surgery.5,6 It is, however, possible in the future, that
radiotherapy might be combined with anticancer drug treatment in this
preoperative setting. A small study has shown that preoperative
radiotherapy in combination with chemotherapy does not compromise
subsequent breast conserving surgery.7
Biosensors are analytic devices that measure biological character-
istics of tissue and body fluids.8 These may be physical parameters
such as O2 concentration and local pH, or more specific biomarkers
such as Caspases.9 The leading example of the use of biosensors in
health care is to monitor diabetes. This point of care testing has
enabled patients to self‐test and manage their own diabetes with sub-
stantial reduction in global health care costs.10
The tumour microenvironment is the cellular setting in which the
cancer exists. It includes blood vessels, immune cells, and inflammatory
cells (see Figure 1). The development of biosensors for real‐time mon-
itoring of the tumour microenvironment offers the promise of clinical
dividends, by connecting an individual tumour's biology to
personalised cancer treatment.11 In addition, chemical biosensors can
be implanted into experimental tumours to detect levels of specific
biomarkers.12 Peptide‐based sensors, using a previously related trypsin
sensor as a model, have been reported.13These may provide a platform
for the measurement of specific markers of interest such as the cas-
pase family of enzymes for cell death. Miniaturised versions of the
ISFET14 (ion‐sensitive field effect transistor) and Clark Electrode sen-
sors15 provide the basis for measuring tumour hypoxia (low levels of
oxygenation) continuously.
Tumour hypoxia is an important factor in both resistance to radia-
tion and chemotherapy.16,17 Radiotherapy requires oxygen to fix radi-
ation damage. It is estimated that about 40% of all breast tumours and
50% of advanced breast cancers contain hypoxic regions.18 In cancer
tumours, demand for oxygen often exceeds supply. The abnormal
and chaotic vasculature of solid tumours can result in temporal and
spatial changes in hypoxia.19,20 However, there is currently no clinically
applicable method of measuring these spatial and temporal changes in
hypoxia in real time, to use this information to the dose distribution
“map” to selectively increase the dose to hypoxic areas during a course
of radiotherapy.Developing real‐time biosensors of breast cancer biology to indi-
vidualise radiotherapy has been identified as a research priority.21 A
cross‐disciplinary project funded by EPSRC, IMPACT (Implantable
Microsystems for Personalised Cancer Therapy) is currently develop-
ing a wireless silicon platform22 to sense real‐time changes in tumour
biology through measurement of pH, oxygenation, and cell death. It
is envisaged that in the future, subject to ethical and other necessary
approvals and validation in preclinical and clinical studies, a number
of biosensors will be inserted into regions of tumour hypoxia. Sensing
hypoxia in real time may allow extra radiation dose to be delivered dif-
ferentially to hypoxia areas (see Figure 1) during a course of curative
radiotherapy, to improve tumour response and cure rates.23
There is a dearth of published literature on the views of cancer
patients on the risks and benefits of tumour biosensors to personalise
radiotherapy treatment.24 Little is known about patient willingness to
accept, albeit hypothetically, implanted devices to improve the out-
come of treatment. It is important to assess acceptability of novel
health care devices among patients at a very early stage to guide future
development, clinical research, and subsequent implementation into
routine practice.
We report, to our knowledge for the first time, the views of breast
cancer patients about the development of real‐time biosensors for
individualised radiotherapy for early breast cancer.2 | METHODS
2.1 | Recruitment
The study adopted a pragmatic approach to obtain a sample of patients
with early breast cancer treated by adjuvant radiotherapy after
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treatment. Potential participants were initially identified and screened
against the eligibility criteria by 4 consultant clinical oncologists
specialising in breast cancer at the postradiotherapy review clinic at
the Edinburgh Cancer Centre.
Inclusion criteriawere adults with a diagnosis of operable early breast
cancer treated by breast conserving surgery or mastectomy, who had
completed their anticancer treatment. Patients who had locally advanced
or metastatic disease or were unable to consent or take part in an
interview, or those vulnerable/unsuitable as screened by the consultants,
were excluded from the study. Women were asked during their
consultation at their postoperative radiotherapy review whether it was
acceptable for the researcher to approach them in the waiting room.
If the response was positive, the researcher offered a Participant
Information Leaflet (PIL; see Appendix S2) and consent form as theywere
leaving. If the consent form was not returned, no follow‐up could be
made. Over a 12‐week period in 2014, 32 women were recruited to the
study, representing 73% of patients whowere approached to participate.
Patientswho declined to participatewere not required to give any reason.
This research was granted ethical approval from National Health
Service Ethics Committee (REC reference number 10/S1103/41).
Participants provided written informed consent prior to being
interviewed. Participation in the study was on a voluntary basis, and
no incentives were offered.
Permission to record the interview was gained to have an accurate
record of the discussion. Most interviews were performed in patients'
homes (N = 28) and a few at the cancer centre (N = 4), based on patients'
preferences. Interviews were recorded by the researchers [TI/GH] with a
digital voice recorder and uploaded to a secure folder on a University of
Edinburgh hard drive. They were transcribed and anonymised by the
researcher [TI]. Transcripts were analysed using qualitative data analysis
software package QSR Nvivo 10 following a standard grounded theory
approach, using a broadly inductive approach, ie, conclusions were
directly driven by the data. Initially, emerging patterns and themes were
captured with an open‐coding method. Following this, they were
grouped into broader coding categories and then further refined into
more abstract themes. Researchers' backgrounds were in the social,
medical, and engineering sciences, covering a range of expertise in
research methods and approaches. Differing viewpoints were discussed,
and reliability of coding was achieved through consensus agreement of
the researchers. An iterative pattern of data collection, reflection/analysis,
further data collection, further reflection and analysis, and finally synthesis
was employed.25,26
The interview focussed on patients' views regarding the use of
implanted biosensors and included possible technological issues related
to the development of biosensors (eg, different shapes, sizes and inser-
tion techniques, data transfer, and data security); see Appendix 1. The
interviews also explored risks (eg, infection), issues around insertion,
and the dwell time for which it was acceptable to retain the sensor.
Patients were presented with standardised written information about
implanted biosensors within the primary tumour and their potential
clinical value (eg, monitoring the cancer's biology and taking real‐time
measurements to individualise future radiotherapy treatment).
During the interviews, all patients were shown medical illustrations
(see Figure 2 as an example), illustrating actual models of biosensors,showing their sizes, shapes, and powering options. The medical
illustrations explained how the biosensor/s would be inserted and
showed 3 options for power and data transmission (wired, part‐wired,
and wireless). Patients were then asked about their preferences in rela-
tion to size and shape of the biosensors, as well as power and data
transmission options. Following good practice in qualitative data
collection methods, a process of review and analysis was applied, and
a pilot interview was performed to test the interview schedule in terms
of patients' understanding and order of questions.273 | RESULTS
Overall, 32 patients took part in a semistructured interview, which lasted
approximately 1 hour. All participantswere adults, female, English‐speaking
patients who had completed their anticancer treatment.3.1 | Patient demographics and breast cancer
experience
Participants were aged between 39 and 87 years; mean age was
62 years. Two thirds of participants were married or had a partner,
and one third, either widowed or separated. The majority (N = 24,
75%) had children (and grandchildren). In relation to how the breast
cancer was detected, there was an almost equal split between
self‐referral/finding a lump and screening mammography (Table 1).
The majority (N = 25, 78.1%) had been treated by surgery adjuvant
radiotherapy and hormonal therapy after breast conserving surgery.
Only 3 (9.4%) had undergone a mastectomy, while 21.9% of patients
(N = 7) had received chemotherapy (see Table 1).3.2 | Familiarity with the concept of biosensors
Most patients (N = 23, 72%) said they had not heard of the term
“biosensor” prior to taking part in this project. Almost one third
(N = 9, 28%) thought they had heard the term or had an idea what it was.3.3 | Patients' general views about biosensors
Of the 32 patients interviewed, almost all (n = 29) were in favour of
allowing a biosensor to be used during treatment.“I suppose, we're talking about potentially saving your life.
I don't see why anybody would not want to have
whatever you need to have in order to get a result.”
(Participant 9)Most patients (N = 29, 90.6%) suggested that they would be sup-
portive of the biosensor technology. Patients tended to be supportive
of the biosensor technology if endorsed and recommended by their
breast cancer consultant:“Yes, I would use it if my doctor suggested it.” (Participant
23)Perceived benefits went beyond the individual patient and often
included family members or the wider group of breast cancer patients
who may benefit from the biosensor technology in future:
FIGURE 2 Example of stimulus material shown to participants (options to power the biosensors)
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others in the future, that's the main thing.” (Participant 1)3.4 | Patients' concerns about biosensors
Only a small number (N = 3, 9.4%) reported uncertainty about whether
they would accept a biosensor in future. Mainly, they were unconvinced
with how it would fit within the framework of their treatment pathway:“See that's quite a hard one to answer in my particular
case, because from diagnosis to surgery was only two
and a half weeks, so, you know, would there even have
been time to do anything in my case, I don't know?”
(Participant 11)Patients acknowledged the discomfort associated with inserting
the biosensors and the potential for complications, such as an infec-
tion, allergic reaction or an embolism. Approximately, half of patients(N = 18, 57%) stated that they would want to know more about the
likelihood of a complication or risk occurring.“I would want to know what the percentages were, so
that [...] you can make an informed decision.”
(Participant 21)3.5 | Size and shape
When discussing the potential size of biosensors, patients tended to
accept any size. Their focus was on “whatever helps to get better,” reit-
erating the theme of recovery from cancer. However, many (N = 28,
88%) did express a preference for a smaller size, perceived as less
intrusive and less painful, especially during insertion.
However, there was a “once it is in, what difference does the
shape make?” philosophy expressed; 54% (N = 17) either did not mind
or were unsure about their preference in relation to shape.
TABLE 1 Demographic, clinical presentation, and treatment features
of the study population
Participants in Sample (n = 32) Frequency Percentage
Age Range
Mean 62 y 39‐87 y (SD = 11.6)
<50 y 3 9.4%
51‐60 y 10 31.2%
61‐70 y 10 31.2%





Widowed/ separated/single 10 31.2%
Family status
Children/grandchildren 24 75%
No children/grandchildren 8 25%
How was breast cancer found
Screening mammography 17 53.1%
Found lump/ self‐referral 15 46.9%
Breast cancer treatment received






(breast conserving N = 4,
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emphasis on a smooth surface with a long shape and rounded edges:“Instinctively when it's got a curved end you think it'll be
less sore going in.” (Participant 7)Although pain on insertion seemed to affect views, again, empha-
sis was placed on the benefits of using biosensors and recovery:“I suppose when you actually think about the process
you've already gone through, and you had the needles
with the biopsies and everything else, if it's going to cure
me or help me get rid of cancer. […] I would say yes, go
for it.” (Participant 5)TABLE 2 Power and data transmission choices
Option
Power (N = Number
of Patients)
Data Transmission
(N = Number of Patients)
Unsure 1 13.6 | Number of biosensors
There was a range of views expressed in relation to the number of bio-
sensors that may be inserted. However, the majority (N = 22, 69%)
expressed a willingness to accept more than 5 biosensors, if this was
required for their treatment.
A small number of patients expressed concerns about having a
higher number of biosensors inserted:Fully wired 1 0
Part wired 1 3
Wireless 29 28“I think I'd draw the line at probably three, I would think.
But again, it would depend on the tumour.” (Participant
27)Yet most patients would agree to have more than 1 biosensor
inserted if this was necessary for their treatment. This view was based
on trust in their health care professional and a focus on recovery.
3.7 | Duration of biosensors in the body
Patients tended to be pragmatic about the dwell time the biosensor/s
were left in the body. If it was small enough, and “it was doing its job”
(Participant 7) and the biosensor could not be felt, then most (N = 22,
69%) were unconcerned about leaving the biosensor in:“As long as they're not doing any more damage, […] you
wouldn't feel them or anything so, yeah, I'd be happy for
them to be there.” (Participant 11)Trust in health care professionals could sometimes override
patients' individual opinion and preference:“I would just go on whatever the doctors recommended.
[…] if they said you need to keep it in for 3 months or
six months or six years or like with the Tamoxifen, for
example, I'm not happy to take that for ten years, but
that's what I'm told to do, so that's what I'm going to
do.” (Participant 9)A minority were wary with having something “foreign” inside
them, and 6 patients (18.5%) expressed a preference to have the bio-
sensor removed once treatment had been completed:“It's a foreign body, and it's not really meant to be there.
And if it's there, it's there for a reason, and if that
reason is now redundant then there would be no need
for them. […] if it was the option to remove them, then I
would probably want it removed.” (Participant 31)3.8 | Power and data transmission options
If a preference was expressed on power and data transmission options,
then most patients (N = 28, 87.5% and N = 29, 90.6%, respectively,
Table 2) favoured a wireless option. Wireless was perceived to be
more convenient, advanced, and less visible on the surface of the skin.
Patients also considered the practical implications of having visible
wires on the surface of the skin. The wired option was perceived as
more obtrusive, especially when getting dressed. It seemed important
not to have anything visible on the surface of the skin. This was seen
as a way of coping with cancer treatment.“Option three [wireless] certainly seems to be the best
one, because then you can always forget it's there, you
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[…] that you do not dwell on it too much when you have
cancer.” (Participant 27)3.9 | Patients' concerns about data security
In general, patients did not express concern around data security. This
was either because patients assumed that data security was taken care
of by the National Health Service and the medical professionals, or
they did not believe that the data could be of interest and use to any-
one else. Some compared the data with their personal financial infor-
mation, concluding that readings from the biosensors would be a lot
less valuable and interesting to other people:“I use a bit of data security when I'm talking about my
bank, but when I'm talking about the status of my
tumour, I don't care who knows.” (Participant 12)In most cases, patients were looking at the “bigger picture” and
their main concern was on getting the best treatment available and
being able to recover:“I wouldn't worry about it [data security]. When you're
going through cancer itself, you wouldn't be thinking
about that; you'd just be thinking of how good this
sensor and technology is that it can actually give a
reading; and it's for your benefit.” (Participant 25)3.10 | Perceived importance of biosensor technology
All patients felt that the biosensor technology was important for the
potential benefit of future cancer patients.4 | DISCUSSION
We present, to our knowledge, the first evidence of support for the
potential future use of implanted biosensors from patients recently
treated for early breast cancer. Implanted biosensors to monitor the
tumour microenvironment may have wider application to other hypoxic
tumours (brain, head and neck, lung, oesophageal, and prostate can-
cer).28 Previous research relating to implantable cardiac devices has
found that in general, patients accepted their devices. However, they
emphasised the importance of assessing patient acceptance to improve
clinical outcome.29 Haddow and colleagues30 explored patients'
reactions to implantable smart technologies, and highlighted that con-
sideration needs to be given to how these technologies affect patients.
Thus, it is vital to consider patient acceptability of novel implantable
technologies to improve future cancer treatment outcomes.
It is recognised that the public perception and understanding of
science are important to adoption of technological advances. In
addition, both scientists and governments may misunderstand public
concern about science and technology.31,32 If public concerns are
misinterpreted, this may result in public dissatisfaction.33 These
arguments equally apply to advances in health technologies in general,
and cancer care in particular.New medical technologies in oncology (as well as other diseases)
require endorsement from patients, as well as cancer professionals
and regulatory bodies assessing safety and clinical efficacy. For exam-
ple, concerns about safety have adversely affected public attitudes to
the use of nanotechnology.34,35
We believe our sample of breast cancer patients, albeit modest as
a pilot study, is reasonably representative of patients treated by sur-
gery and postoperative radiotherapy for early breast cancer. Over
75% of patients had been treated by breast conserving surgery and
postoperative radiotherapy, the most common treatment policy for
early breast cancer. We, therefore, think the sample was representa-
tive of standard care. Most patients had received some form of adju-
vant systemic therapy. It has been our local policy in patients
requiring adjuvant chemotherapy for this to be performed after sur-
gery but before radiotherapy. There is normally 1 postradiotherapy
visit (6‐8 wk after the completion of radiotherapy) before patients
are referred back to surgical unit for annual follow‐up. Hence, review
in the postradiotherapy clinic, the setting for this study, involved
patients who had relatively recently completed and recovered from
their postoperative radiotherapy.
Qualitative research is valuable as it increases understandings
around why individuals would be willing to accept a technology. As this
study also reiterates findings from earlier work with men recovering
from prostate cancer,24 a degree of confidence regarding the validity,
transferability and reliability of the present data, can be assumed.36
It is encouraging that most patients (29/32) [90.6%] were in
favour of the idea of biosensors being implanted to improve breast
cancer treatment. The endorsement of their cancer specialist was a
strong factor influencing this view. This is consistent with the trust that
breast cancer patients in general invest in the views of their specialist
clinicians over the best treatment for them.37 Of note, patients consid-
ered the benefits not just to themselves but to the wider population of
breast cancer patients. This is consistent with altruism being an impor-
tant factor in participation in cancer clinical trials.38,39 We need to be
cautious in interpreting support among patients for biosensors for a
number of reasons. First, the technology is at a very early stage of
development and in advance of any prototype, so the medical illustra-
tions of the size and shape of the biosensors and how many biosensors
might be inserted are putative. Secondly, as with any health care tech-
nology, there is a trade‐off between clinical benefits and risks. We
were not able to present any specific information to patients about
the type and frequency of side effects of implanting the devices (pain,
infection, biofouling, malfunction) and benefits (reduced risk of recur-
rence, improved survival) for monitoring the biology of their breast
cancer for treatment purposes. Changes in the risk/benefit ratio, once
this information is available in the future from early phase clinical trials,
are likely to be more informative to patients. Other factors such as the
requirement for a separate general anaesthetic, with associated, albeit
small risks, might also reduce patient support. However, the main pur-
pose of the study was to try and explore at an early stage in the devel-
opment whether patients identified major concerns that have to be
addressed before early phase trials and clinical implementation could
be considered. We can envisage that in the future the use of biosen-
sors of hypoxia may add valuable information to the radiotherapy plan-
ning “map.” This would allow the distribution of radiation energy to be
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therapy treatment of breast cancer and other hypoxic tumours.
It is useful to know that patients expressed a strong preference for
biosensors that worked wirelessly, with no protruding wires from the
device to the surface of the skin. This is in line with other devices such
as cardiac pacemakers that are placed subcutaneously to detect abnor-
mal cardiac rhythms to maintain cardiac function. These are widely
accepted by patients.29 Some patients in our study may have been
aware of the availability of a variety of wearable devices to measure,
for example, heart rate. These devices collect physiological data in real
time so patients tended to be familiar with wearable devices. The step
to measure the biological activity of their cancer might not be too great
a conceptual leap. However, we did not question patients about their
knowledge of wearable devices.
There was a limited number of patients who felt uncertain whether
theywould accept a biosensor as part of their treatment.However, their
concerns were not related to risk about the device but to uncertainty
about how the biosensor might fit into the patient treatment pathway.
This is not surprising because it is too far from clinical implementation
to predict how biosensors will fit into the treatment framework.
It is perhaps surprising that patients did not express more concern
about confidentiality. This might be because they assumed that confi-
dentiality would be maintained if the device was approved by NHS
regulatory bodies. Cybersecurity is a legitimate concern with the risk
of ill‐intentioned individuals or organisations hacking into IT used by
the device, stealing confidential information or causing the device to
malfunction. An increase in NHS cybersecurity breaches could
adversely affect support from both patients and cancer professionals
for biosensors in the management of breast cancer and other hypoxic
cancers.
Willingness to accept implanted biosensors is not gender specific,
as previous research with male participants,24 and this study with
female participants have shown that both men and women recovering
from cancer express some degree of acceptance. However, the impact
of having recovered from cancer on this willingness to accept is not
clear. Further research with other subgroups of the population may
be required.4.1 | Study limitations
We recognise there are some limitations of this pilot study. The
information presented to the patients on the size and shape of the bio-
sensors is conjectural, since the biosensors are still in the design phase
prior to testing in murine and veterinary tumour models to show “proof
of principle.”22 It is likely that their eventual size, shape, and optimal
number will be determined by further preclinical and clinical research.
We recognise that preoperative radiotherapy in breast cancer remains
investigational and may or may not become part of standard care in the
future. It is possible, therefore, that the use of biosensors to individu-
alise radiotherapy planning based on real‐time spatial and temporal
measurements of hypoxia may find its initial applications in other solid
hypoxic tumours (eg, brain, head and neck, lung, oesophagus, prostate,
and cervix), in which radical radiotherapy with or without systemic
therapy is the primary treatment where the tumour has not been
removed surgically.To explain the insertion of biosensors, we did use the analogy of
patients having titanium clips inserted at the time of diagnostic biopsy
or after breast conserving surgery to mark the tumour bed. However,
as yet, the exact method of insertion is still at a research and develop-
ment level preclinically.
This study only included patients who had completed their anti-
cancer treatment, which means that the views of patients still under-
going treatment were not captured. Moreover, this study was
performed in a single location. These limitations may have implications
for the generalisability of the sample.
This study was not designed for and it was not a questionnaire of a
representative sample to infer associations between demographics,
and considering the sample size and single location of the study, infer-
ential statistics were not performed. It might be worth doing a study
designed specifically for that in the future.4.2 | Clinical implications
The development of electrochemical biosensors for real‐time monitor-
ing of tumour microenvironment has potentially promising clinical div-
idends by connecting individual patient biology to individualised
cancer treatment.5 | CONCLUSION
We can conclude from this study of patients' views of biosensors at a
very early stage of development that none of the technology's potential
downsides would preclude their further development for radiotherapy
treatment of breast cancer. This helps justify the costs of continuing
to invest in further research and development towards early clinical
testing of biosensors for breast cancer and other solid tumours. If pre-
clinical and clinical “proof of principle” is demonstrated in the IMPACT
study,22 larger scale studies of patients' views at a more advanced stage
of this novel technology will be needed to confirm our findings.
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